恶性骨肿瘤患者的可溶性p185（HER-2）
Soluble p185(HER-2) in patients with malignant bone tumours.
作者信息
Holzer G, Pfandlsteiner T, Koschat M, Noske H, Trieb K, Kotz R
机构信息
Department of Orthopaedics, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
出版信息
Pediatr Blood Cancer. 2005 Feb;44(2):163-6. doi: 10.1002/pbc.20217.
BACKGROUND
This study was initiated to test the hypothesis that soluble p185(HER-2) could be of value as a diagnostic or predictive marker for patients with malignant bone tumours.
PROCEDURE
Sera of 35 patients with high-grade malignant osteosarcoma (n = 27) and Ewing Sarcoma (n = 8) were tested at the time of diagnosis by ELISA and compared with sera of controls (n = 38) and clinical data.
RESULTS
In patients with osteosarcoma and Ewing Sarcoma, levels of sp185(HER-2) did not differ significantly from levels in controls. These results were irrespective of the type of tumour, survival chemotherapy or other clinical variables.
CONCLUSION
p185(HER-2) serum levels do not appear to be of diagnostic or predictive value for differentiation of high-grade osteosarcoma and Ewing Sarcoma.
背景
本研究旨在验证可溶性p185（HER-2）作为恶性骨肿瘤患者诊断或预测标志物的价值这一假设。
过程
在诊断时，采用酶联免疫吸附测定法（ELISA）检测了35例高级别骨肉瘤患者（n = 27）和尤因肉瘤患者（n = 8）的血清，并与对照组（n = 38）的血清及临床数据进行比较。
结果
骨肉瘤和尤因肉瘤患者的sp185（HER-2）水平与对照组相比无显著差异。这些结果与肿瘤类型、生存化疗或其他临床变量无关。
结论
p185（HER-2）血清水平对于高级别骨肉瘤和尤因肉瘤的鉴别似乎没有诊断或预测价值。
Zotero 插件